We surveyed all people who were diagnosed with lung cancer from 1 January to 30 June 2003 and identified by the Victorian Cancer Registry; p o s t m or t e m d i ag n os e s w er e e xcluded. Ethics approval wa s obtained from the Cancer Council Victoria Institutional Ethics Committee. A questionnaire relating to management was sent to the treating clinicians, and non-responding clinicians were actively followed up to obtain data. Comorbid conditions were scored according to the Colinet simplified comorbidity score.
The Medical Journal of Australia ISSN: 0025-729X 18 November 2013 199 10 674-679 ©The Medical Journal of Australia 2013 www.mja.com.au Research ung cancer is the greatest single cause of cancer death in Aust ra li a for bot h me n a nd women. 1, 2 Despite Australia having some of the best outcomes internationally, the 5-year relative survival rate is less than 15%. 2, 3 Our previously reported survey of cases of lung cancer, reported to the Victorian Cancer Registry in the first half of 1993, identified opportunities to improve patient management. 4, 5 Since that time, there have been a number of important developments in staging and treatment for this disease. [6] [7] [8] In this study, 10 years on, we present the results of a detailed survey of Victorian patients who presented with lung cancer in 2003 and who were followed for 5 years to provide updated and additional information, including changes over the decade.
Results
Nine hundred and twenty-one eligible cases were reported and 841 (91.3%) were included in the survey. Reasons for cases not being included were: doctor refusing or being unavailable (48); record unavailable (21) ; and other (11) . The characteristics of the 841 patients are shown in Box 1. For 194 patients (23.1%), lung cancer was diagnosed in the absence of symptoms, mostly as a result of imaging performed for other reasons. Only 16 patients (1.9%) were diagnosed by a screening chest x-ray and/or computed tomography scan. Thirty-three patients (3.9%) were recruited to a clinical trial.
Non-small cell lung cancer
The characteristics and management of the 655 patients with non-small cell lung cancer (NSCLC) are shown in Box 2 and Box 3. Weight loss was evident in 270 patients (43.8%), and 87 (14.1%) had lost more than 10% of their bodyweight.
Treatment was considered to have had curative intent based on the information available in the health records, despite no apparent curative treatment being given to six patients with NSCLC. Of the 125 patients treated surgically with curative intent, 97 (77.6%) underwent positron emission tomography (PET) scanning before surgery. All but eight of the 23 patients who did not have a Lung cancer in Victoria: are we making progress?
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Objectives: To identify areas to improve patient management in lung cancer, which remains the greatest cause of death from cancer in Australia.
Design and setting: Retrospective survey of all cases of lung cancer reported to the Victorian Cancer Registry from 1 January to 30 June 2003 and followed up for 5 years.
Main outcome measures: Patient and disease characteristics, investigations, staging, treatment, cause of death, survival.
Results: 841 patients were included. Smoking data were available for 799, of whom 63 (7.9%) had never smoked. Of 655 non-small cell lung cancer (NSCLC) cases, 198 (30.2%) were treated with curative intent, 125 (19.1%) by surgery and 73 (11.1%) by radiotherapy with or without chemotherapy. Only 7 (6.9%) of surgical patients with complete R 0 resection had adjuvant chemotherapy. Of 101 small cell lung cancer (SCLC) cases, a third had limited stage disease which was mostly treated with curative intent by chemotherapy with or without radiotherapy. Patients whose cases were discussed at a multidisciplinary meeting (MDM) were significantly more likely to receive anticancer treatment and had longer survival; on multivariate analysis, MDM discussion was an independent prognostic factor. Compared with a similar survey 10 years earlier, the median age of patients diagnosed with lung cancer had increased by almost 3 years, the proportion of affected men decreased and adenocarcinoma was more frequent, while 10% of patients continued to have no pathologically confirmed diagnosis and 26% continued to receive no anticancer treatment. The number of patients with NSCLC who went on to a definitive surgical procedure fell with no detriment to survival, which likely reflected better staging with the introduction of positron emission tomography scanning.
Conclusions: Opportunities to improve patient management included increasing the proportion with a pathologically confirmed diagnosis and greater use of postsurgical adjuvant chemotherapy. A high proportion of patients received no treatment, with underuse of chemotherapy and radiotherapy. Critically, the low rate of case discussions at MDMs needs to increase. However, effective strategies are required to identify cases early, as over two-thirds currently present with incurable disease.
PET scan had Stage I disease. Adjuvant chemotherapy was administered to seven patients of the 101 with complete (R 0 ) resections, including two of 21 with Stage II-IIIA disease and two of 25 with Stage IB disease. Of the 24 patients who had incomplete (R 1 or R 2 ) resections (R 1 , 23; R 2 , 1), 18 received additional treatment: this was radiotherapy alone for 11 patients and chemoradiotherapy for seven.
Fifty-three of the 73 patients treated with radiotherapy with curative intent also received chemotherapy, which was concurrent for 26 patients and sequential for two, while the schedule was unknown for 25. A PET scan was performed before curative radiotherapy for 61 (83.6%).
Chemotherapy was administered at some time, with curative or palliative intent, to 258 (39.4%) patients with NSCLC, and radiotherapy to 365 (55.7%).
The median survival time for patients with NSCLC was 6.9 months (SE, 0.42 months) with a 5-year crude survival rate of 10.8%. The median and 5-year survivals for patients treated with curative intent by surgery were 45 months (SE, 4.4 months) and 43.2%, respectively, and by radiotherapy or chemoradiotherapy 14.8 months (SE, 4.6 months) and 19%, respectively, while the median survival time with palliative treatment was 5.7 months and, with no active treatment, 4 months (P < 0.001). Most patients died from their lung cancer, but the cause of death was not the index lung cancer for 44 patients (6.7%), while for five (0.8%), the cause of death was unknown.
Small cell lung cancer
The characteristics and management of the 101 patients with small cell lung cancer (SCLC) are detailed in Box 2 and Box 3. The median survival time for patients with SCLC was 7.2 months (SE, 0.96 months) with three patients (3.0%) surviving 5 years. Patients treated with curative intent had a median survival time of 12.8 months (SE, 6.0 months) and a 5-year survival rate of 11.1%. The cause of death was not the index lung cancer for five patients (5%), while for one, the ca use of death was unknown.
Clinical diagnosis only
The characteristics and management of the 85 patients with a clinical diagnosis (CD) only of lung cancer are detailed in Box 2 and Box 3. For 53, there was an attempt to obtain a pathologically confirmed diagnosis by cytological examination of sputum, bronchoscopy or biopsy.
Patients with CD only, when compared with those with a diagnosis confirmed by pathology testing, were older (median age, 79 years v 71 years; P < 0.001), had a lower Eastern C o o p era t iv e O nc o logy G ro u p (ECOG) performance status (PS) score (0-1, 13% v 51%; P < 0.001), and were less likely to be referred to a specialist (83.5% v 99.1%, P < 0.001) or discussed at a multidisciplinary meeting (MDM; 11% v 30%; P = 0.001), less likely to be treated with curative intent (2% v 31%; P < 0.001), and more likely to receive no anticancer therapy (84% v 20%; P < 0.001). Patient outcomes were worse for the CD cohort, with a median survival time of 1.1 months (SE, 0.2 months) v 6.9 mo nt hs (SE, 0 .4 m on ths) (P < 0.001); 56 CD patients (66%) died within 2 months of diagnosis. (20) ; and travel distance (two). The cohort of 163 patients not offered therapy and for whom data were available included some who might have benefited from therapy, including 12 (7.4%) with stage I/II disease, 74 (45.4%) with ECOG PS scores of 0-2, 37 (22.7%) with low Colinet simplified comorbidity scores of 0-6, and 9 (5.5%) who had never smoked.
Smoking
Among 799 patients with available data on smoking, 63 (7.9%) had never smoked. Overall, 45 of the 63 who had never smoked (71%) were women. Thus, a much higher proportion of women (15.3%; 45 of 294) than men (3.6%; 18 of 505) had never smoked (P < 0.001). Previous smokers had stopped smoking a median of 12 years earlier. Among all smokers, the median pack-years (PY) was 50, and there was a significant difference by sex in smoking exposure at the time lung cancer was diagnosed, with a median of 37 PY for women and 52 for men (P < 0.001).
For NSCLC, there was a trend for fewer current smokers to present with early-stage disease, with 35 of 203 (17.2%) presenting with Stage I/ II disease compared with 13 of 50 of those who had never smoked (26%) and 87 of 335 previous smokers (26%) (P = 0.057).
Among all patients with lung cancer, 55 of the 63 who had never smoked (87.3%) died within 5 years of diagnosis, 51 of lung cancer and four (6.4%) from other causes. The proportion of current and ex-smokers dying from causes other than the index lung cancer was similar: 12 of 278 (4.3%) and 31 of 458 (6.8%), respectively. Patients whose cases were discussed at an MDM were more likely to receive active treatment (190 of 233 [81.6%] v 397 of 563 [70.5%]; P = 0.004) and had improved survival ( 1 0 . 8 m o n t h s v 5 .5 m o n t h s; P < 0.001). As early death may have prevented case discussion, a landmark analysis (an analysis at a point in time) was carried out including only those surviving for 2 months or longer, which also showed a significant benefit (13.3 months v 9.3 months; P < 0.001). A multivariate Box 5 shows that the median age at diagnosis had increased by 34 months over the 10 years since the previous survey. 4 This compares with a 10-month increase in age for all cancers over the previous decade (data not shown) (P < 0.001). There was no significant change in survival when adjusted for age.
Discussion
In this study we were able to obtain data for over 90% of reported cases which is a high proportion compared with some other studies. 10 Although 92.1% of patients had smoked, only a third were current smokers. For smokers with lung cancer, exposure to tobacco, as indicated by pack years, was 29% less for women, which is consistent with the previously reported observation that women are more susceptible to carcinogens in tobacco smoke.
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There was no pathologically confirmed diagnosis for 10.1% of Victorian patients, which was a lower percentage than in New South Wales, Queensland, New Zealand and the United Kingdom. 10, [12] [13] [14] Patients with no pathologically confirmed diagnosis had a median survival time of just over a month, and very few received treatment. It is unclear if any of these patients might have benefited from treatment, and some may have had non-malignant but fatal conditions such as tuberculosis.
Of all Victorian patients with lung cancer, 97.5% (820 of 841) were referred to a specialist before treatment, which is considerably higher than in NSW, Scotland and New Zealand. 10, 13, 15 Although initial referrals to palliative care physicians were infrequent, over 40% of cases later involved palliative care physicians. The proportion of all cases discussed at an MDM was low at 29% (234 of 797 with available data), similar to New Zealand, but has increased to 49% more recently. 13, 16 Patients whose cases were discussed at an MDM were more likely to be treated and had significantly better survival. Although cases that were discussed had a number of good prognostic features, on multivariate analysis (rerun with MDM added), discussion at an MDM was an independent prognostic factor for survival. Other researchers have identified more frequent active treatment 17 as well as improved survival 13 associated with discussion at an MDM. However, our data indicating that the survival benefit is maintained in both a landmark and a multivariate analysis provide a strong rationale for all cases to be discussed at an MDM.
The use of PET scan staging in about 43% (283 of 655) of all and 80% (158 of 198 [comprising 97 of 125 surgical patients and 61 of 97 patients treated with radiotherapy]) of curative NSCLC cases was considerably higher than in NSW. 10 PET scans are particularly useful in mediastinal staging and identifying unrecognised metastases. 6 Despite about 26% of patients with NSCLC having Stage III disease, only around 8% (51 of 655) had invasive staging of the mediastinum, suggesting that some who underwent surgery or radiotherapy were inadequately staged.
Around 30% of patients with NSCLC underwent treatment with curative intent, including 19.1% going to surgery, which is a higher proportion than in NSW, New Zealand and the UK. 10, 13, 14 Adjuvant chemotherapy rates were very low despite trials supporting adjuvant chemotherapy having just been reported at conferences by 2003. 18 Overall, around 11% of patients with NSCLC underwent radiotherapy with curative intent, with about 73% (53 of 73 with available data) being given as concurrent chemoradiation, which is the standard of care. 8 The use of both chemotherapy 19 and radiotherapy 20 was low, although higher than in NSW. 10 Over 21% of patients diagnosed with NSCLC received no treatment at all, which is of concern, although this rate was lower than that in NSW 10 and the UK. 14 We have not analysed this group closely but as more effective therapies with low toxicity (eg, epidermal growth factor receptor inhibitors) become available, it is likely that many patients will be suitable for molecular therapies despite not being suitable for chemotherapy.
As expected, around a third of patients with SCLC had limited stage disease, and most were treated with curative intent. These patients generally received chemotherapy along with thoracic radiotherapy, which is standard of care. 21 It has been widely reported that outcomes for patients with lung cancer Australia who live outside major metropolitan centres are worse, 2 but we did not see any significant difference in this study after adjusting for age and sex. However, on multivariate analysis, survival was significantly worse for two of the regional/rural cancer networks. These data would need to be confirmed by an analysis covering a longer time period, as the annual number of cases was small.
As in many other developed countries, the proportion of women with lung cancer increased over the decade from 1993 to 2003 while the proportion of patients with SCLC continued to decrease and, for patients with NSCLC, adenocarcinoma became more frequent than squamous cell carcinoma. The age of patients diagnosed with lung cancer increased by almost 3 years, considerably more than for other cancers. This may have been due to changing smoking habits, with patients in the more recent cohorts having not smoked as heavily as those in earlier cohorts, while this reduced intensity of tobacco exposure was associated with a later onset of the malignancy. 22 The use of PET scanning increased considerably while the proportion of patients with NSCLC undergoing surgery with curative intent dropped by 6.2% (Box 5). It is likely that PET scanning prevented some patients going to surgery by identifying occult mediastinal or metastatic disease, with no detriment to survival. The use of combination chemoradiotherapy was much more frequent in 2003 than a decade earlier, in line with guidelines and best practice. 8 On the other hand, pathologically confirmed staging of the mediastinum was infrequent. Since 2003, imaging and biopsy by endobronchial ultrasound has become more widely available, obviating the 24 Relative survival refers to the survival detriment compared with the age matched population without lung cancer.
Our approach in this survey, where we analysed a cohort followed for 5 years, means that our findings may not represent current practice. In light of this, a lung cancer registry has recently been established in Victoria, where cases are identified at diagnosis and data are collected prospectively.
L ung cancer survival clearly remains very poor, and although some progress has been made in better staging and greater use of multimodality therapy, our study has identified several areas that require improved patient management. These include increasing the proportions of patients who receive tissue diagnoses, receive active treatment, have PET scans (if curable), and receive postsurgical adjuvant chemotherapy. Of critical importance, our data support all cases of lung cancer being discussed at an MDM, which appears to be associated with a survival advantage. However, it is important to recognise that despite these measures, twothirds of patients will continue to present with incurable disease. Besides tobacco control, early diagnosis is crucial, and this may be achieved by measures such as screening of smokers by low radiation dose computed tomography scanning.
